Effect of osimertinib in ethnic Chinese with EGFR and T790M mutated NSCLC

Study identifier:D5160R00016

ClinicalTrials.gov identifier:NCT03133234

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Observational, Retrospective, Real World Study of osimertinib in Ethnic Chinese Patients with Locally advanced/Metastatic T790M Mutation-Positive non-small-cell lung cancer (NSCLC )progressed on previous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

Medical condition

T790M positive NSCLC patients

Phase

N/A

Healthy volunteers

Study drug

osimertinib

Sex

All

Actual Enrollment

Study type

Observational

Age

18 Years +

Date

Study Start Date: 23 May 2017

Primary Completion Date: 13 Sept 2017

Study Completion Date: 13 Sept 2017

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -

Verification:

Verified 01 Nov 2018 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Location

Kiang Wu Hospital

Macau, China

Arms	Assigned Interventions
EGFR T790M Patients Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI	Drug: osimertinib Oral dose of 80mg once daily Other Name: NA

"There is no result for the study"

Documents available

CSR Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Investigators

Principal Investigator

Yabing Cao

Kiang Wu Hospital

Effect of osimertinib in ethnic Chinese with EGFR and T790M mutated NSCLC

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Kiang Wu Hospital

Documents available

CSR Synopsis

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator